Dyne Therapeutics (NASDAQ:DYN) Director Sells $3,122,168.80 in Stock

Posted by Brenda Bartman on Jun 29th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Jason Rhodes sold 147,760 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $21.13, for a total transaction of $3,122,168.80. Following the sale, the director owned 1,106,036 shares of the company’s stock, valued at approximately $23,370,540.68. The trade was a 11.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $20.94 on Monday. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00. The firm’s 50-day moving average is $18.45 and its 200-day moving average is $18.08. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The company has a market cap of $3.46 billion, a P/E ratio of -6.50 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the firm posted ($1.05) earnings per share. On average, equities analysts expect that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC acquired a new position in shares of Dyne Therapeutics during the 1st quarter valued at $26,000. Strs Ohio acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at $51,000. Aster Capital Management DIFC Ltd bought a new position in Dyne Therapeutics during the fourth quarter valued at about $84,000. Steward Partners Investment Advisory LLC grew its holdings in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Dyne Therapeutics by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after acquiring an additional 1,440 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DYN has been the topic of a number of analyst reports. Morgan Stanley dropped their price objective on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. TD Cowen initiated coverage on shares of Dyne Therapeutics in a research note on Friday. They issued a “buy” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Sanford C. Bernstein raised their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

View Our Latest Research Report on Dyne Therapeutics

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.